The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023(Supplement) Cellular Brain Repair for Parkinson’s Disease: Preclinical Therapeutic Validation of Biomaterial-supported Cell Transplants Coupled with Immunosuppression
Study Rationale: Although transplantation of stem cell-derived brain cells is a promising therapeutic approach for Parkinson’s disease (PD), only a small fraction of the cells that are transplanted...
-
Data-Driven Subtyping and Stratification Program, 2023Identifying Distinct Patterns in Parkinson’s Disease Progression Using Integrative, Data-driven Subtype Analysis
Study Rationale: Parkinson’s disease (PD) is associated with diverse motor and non-motor manifestation that progress gradually over time. Although this progression differs from individual to...
-
Translational Pipeline Program, 2023Evaluating Use of a Spinal Cord Prosthesis to Alleviate Locomotor Deficits in Parkinson’s Disease
Study Rationale: Over the past two decades, we have developed a therapy that restores walking after paralysis due to a spinal cord injury. This therapy uses an implanted neurostimulation prosthesis to...
-
Aligning Science Across Parkinson's, 2023(Supplement) Exploring the Mechanisms by which Co-pathologies Drive Neuroinflammation and Progression in Parkinson’s Disease
Study Rationale: Although Parkinson’s disease (PD) is considered a synucleinopathy, the clinical progression of PD is driven by additional pathological proteins such as tau and beta amyloid. We...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Using a Virally Encoded, Single-chain Antibody as a Noninvasive Gene Therapy for Parkinson’s Disease
Study Rationale: The main pathological hallmarks of Parkinson’s disease (PD) are the degeneration of dopamine-producing brain cells and the accumulation of protein aggregates containing misfolded...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program - Therapeutics, 2023Assessing the Ability of Dapansutrile, a Selective, Oral Inhibitor of the NLRP3 Neuroinflammatory Pathway, to Mitigate Progression of Parkinson’s Disease
Study Rationale: Increasing scientific data indicate the role of neuroinflammation in the pathology of Parkinson’s disease (PD) and related alpha-synucleinopathies. Dapansutrile (lab code: OLT1177®...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.